Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03208023 · ClinicalTrials.gov registry record · NA
RESIPI for Reducing Perioperative Major Adverse Cardiac Events
A NA study, sponsored by Vanderbilt University Medical Center.
- Terminated
- Registry status
- NA
- Development phase
- 155
- Enrollment target
NCT03208023 is a NA study that was terminated before completion, run by Vanderbilt University Medical Center. The registered enrollment target is 155 participants.
The verdict
NCT03208023, a NA study, was terminated before completion, sponsored by Vanderbilt University Medical Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 155 participants
- Enrollment target
Study Summary
This study aims to evaluate the effect of a novel hemodynamic management and monitoring strategy for reducing cardiac bio marker elevations and major adverse cardiac events.
Interventions
- OTHER No intervention
- PROCEDURE RESIPI Management Strategy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2017-10-09 |
| Est. Completion | 2018-12-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03208023
The ClinicalTrials.gov registry entry for NCT03208023 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 155 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which No intervention is the first listed.
NCT03208023 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03208023 about?
NCT03208023 is a clinical study titled "RESIPI for Reducing Perioperative Major Adverse Cardiac Events". This study aims to evaluate the effect of a novel hemodynamic management and monitoring strategy for reducing cardiac bio marker elevations and major adverse cardiac events.
What is the current status of trial NCT03208023?
This trial is currently terminated. It is a NA study. The enrollment target is 155 participants. The study started on 2017-10-09. Estimated completion is 2018-12-03.
What interventions are being tested in trial NCT03208023?
The interventions under investigation include: No intervention (OTHER), RESIPI Management Strategy (PROCEDURE).
Who is sponsoring clinical trial NCT03208023?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.